ClinicalTrials.gg
RecruitingNCT06749834Updated Feb 24, 2025

Intravenous Thrombolysis and NOAC

A Phase 3 interventional study of Intravenous thrombolysis in Acute Ischemic Stroke, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies testing thrombolytics in Ischemic Stroke — 41 open to participants now, 41 under way, 31 of them phase 3. A drug class: Thrombolytics · Ischemic Stroke.

Planned enrollment
56th of 101
280 · median 324
Started
2025
with 15 others
Phase 3
54 of 101
29 open now
Primary completion
2026-12
later than 9 of 40 live
Registered
73rd of 101
by date
Lead sponsor
5 of 101
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 101 studies testing thrombolytics in Ischemic Stroke, this one is the 56th largest by planned enrollment, is one of 16 that started in 2025, is one of 54 in phase 3, reaches primary completion later than 9 of the 40 other live ones, and was the 73rd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 101 studies testing thrombolytics in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:

36 more — sign in →

By country, each count listing its studies:

All 41 open studies →

About thrombolytics

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies testing thrombolytics in Ischemic Stroke, or all of them as a file.
02

Study summary

New oral anticoagulants (NOACs), including rivaroxaban, apixaban, dabigatran, and edoxaban, have become the first-line therapy for preventing ischemic stroke associated with non-valvular atrial fibrillation (NVAF). Despite the effectiveness of NOACs in preventing thromboembolic events, approximately 1% to 2% of patients taking NOACs experience an ischemic stroke annually. Intravenous thrombolysis is an important means of treating acute ischemic stroke (AIS). However, due to concerns about the risk of symptomatic intracranial hemorrhage (sICH) or other severe bleeding complications, current guidelines still consider the use of NOACs within 48 hours before symptom onset as a contraindication to intravenous thrombolysis. Epidemiological data suggest that this may result in up to 18% of AF patients being unable to receive intravenous thrombolysis when they have an AIS episode.

Previous animal experiments have shown that NOACs do not increase the risk of hemorrhagic transformation after intravenous thrombolysis. Pharmacokinetic studies have demonstrated that 24 to 48 hours after taking NOACs, the anti-Xa level in patients is relatively low (\<0.5 U/mL). In recent years, multiple retrospective studies and meta-analyses have shown that prior use of NOACs does not increase the risk of sICH in AIS patients receiving intravenous thrombolysis, and there are no significant differences in functional outcomes at 3 months. With solid pharmacokinetic and retrospective clinical evidence to support, it is hypothesized that IVT are safe in IS-NOAC patient. The investigators hereby propose a prospective multicenter study to determine the efficacy and safety of IVT in acute IS-NOAC.

Read the detailed description

In this prospective cohort study, the investigators aim to recruit consecutive IS-NOAC patients who met the inclusion criteria. The investigators sought to determine the safety and efficacy of IVT in acute ischemic stroke patients on NOACs. It is hypothesized that for IS-DOAC patients with the last intake of NOAC within 48 hours, IVT improved neurological outcomes with acceptable safety compared to a cohort of acute IS-NOAC patients excluded from IVT.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Intravenous thrombolysis
  • outcome
  • NOAC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with clinical signs of acute ischemic stroke within 24 hours of onset or awakening with stroke (if within 24 hours from the midpoint of sleep). Patients with AIS within 4.5-24 hours of onset must meet the IVT inclusion criteria specified in the guideline
  2. Patients with new oral anticoagulants usage within 4-48 hours of onset;
  3. Patients ≥ 18 years old
  4. has been obtained depending on local ethics requirements.

Exclusion criteria

Exclusion Criteria:

  1. Intended to proceed to endovascular treatment
  2. With >40s
  3. Pre-stroke mRS score > 2
  4. for IVT:
  1. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hematoma, etc.) 2) Previous history of intracranial hemorrhage 3) Severe head trauma or stroke history within the last 3 months 4) Intracranial tumors, giant intracranial aneurysms 5) Intracranial or spinal surgery within the recent 3 months 6) Major surgical procedures within the last 2 weeks 7) Gastrointestinal or urinary tract bleeding within the last 3 weeks 8) Active visceral bleeding 9) Aortic arch dissection 10) Arterial puncture in a site within the last 1 week that is not easy to compress and stop bleeding 11) Elevated blood pressure: Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg 12) Acute bleeding tendency, including count \< 100 × 10⁹/L or other conditions 13) Received low-molecular-weight heparin treatment within 24 hours 14) Oral anticoagulants (warfarin) with INR > 1.7 or PT > 15 s 15) Blood sugar \< 2.8 or > 22.22 mmol/L 16) Head CT or MRI indicates large-area infarction (infarction area ≥ 1/3 of the middle cerebral artery supply area) (4) The judgment is left to the discretion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Intravenous thrombolysis

    Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg),intravenous Tenecteplase(0.25mg/kg,administered as a single intravenous bolus injection over 5 - 10 seconds,with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

    Drug: Intravenous thrombolysis

  • No intervention
    Standard therapy

    Standard therapy

Interventions

  • DrugThrombolyticsStudies of ThrombolyticsThrombolytics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg),intravenous Tenecteplase(0.25mg/kg,administered as a single intravenous bolus injection over 5 - 10 seconds,with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

06

What researchers measure

Primary outcomes

  1. Excellent recovery assessed by the ratio of modified Rankin Scale (mRS) score of 0-1 (%) at 90 ± 7 days

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

Secondary outcomes

  1. the change on the National Institute of Health stroke scale (NIHSS) score from baseline to 1 day

    NIHSS: minimum value = 0, maximum value = 42, and higher scores mean severer symptoms

    Time frame: from baseline to 1 day

  2. Independent recovery assessed by ratio of modefied Rankin Scale (mRS) score of 0-2 (%) at 90 ± 7 days

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

  3. recovery assessed by modefied Rankin Scale (mRS) score

    mRS: minimum value = 0, maximum value = 6, and lower scores mean a better outcome

    Time frame: 90 ± 7 days

  4. 3-month mortality

    Hospitalization records or follow-up results

    Time frame: 90 ± 7 days

  5. Presence of parenchymal hemorrhage (PH)

    the presence of PH is defined according the standard from ECASS-2 study

    Time frame: at day 1

  6. Presence of symptomatic intracerebral hemorrhage (sICH)

    the presence of sICH is defined according the standard from ECASS-2 study

    Time frame: at day 1

  7. Presence of hemorrhagic transformation

    Presence of hemorrhagic transformation is defined according the standard from ECASS-2 study

    Time frame: at day 1

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Protecting the privacy of participants is a priority, and sharing IPD could potentially compromise this.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 23 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 27, 2024
StartActual
Jan 27, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06749834
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Jan 27, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 24, 2025

Study contacts

Min Lou, PhD, MD
Contact
lm99@zju.edu.cn
8613958007213
Wansi Zhong, MD
Contact
21718233@zju.edu.cn
8618757155806

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thrombolytics

Start the discussion